What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
DDW Editor Reece Armstrong examines some of the science that has emerged in the last year that is driving the conversations at SLAS 2026. SLAS always provides a great opportunity to assess what topics are in the minds of scientists within the drug discovery… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More
News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW. This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories: Parkinson’s could be identified in… Read More
Researchers have made a groundbreaking discovery into why some forms of breast cancer are drug resistant. Cancer scientists at City St George’s, University of London found a ‘molecular signature’ drives drug resistance in an aggressive type of breast cancer known as HER2-positive breast cancer. The… Read More
What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More
What if you could see disease coming years before symptoms appear? Chronos makes that vision a reality. Built on 100 million plasma samples from six million US donors, the platform combines real-world clinical data with high-resolution proteomics to chart molecular changes across time and populations. In this… Read More
Watch this DDW listicle exploring how biomarkers are reducing risk in drug discovery and clinical trials, sponsored by Olink. As drug development becomes increasingly complex, smarter decisions depend on having the right biological data at the right time. In this video, hosted by Drug Discovery World (DDW) and… Read More
In this video, hosted by Drug Discovery World (DDW) and sponsored by Olink, we highlight how protein biomarker insights are helping researchers improve target selection and make more informed decisions across the R&D pipeline. Read More
A new study has revealed that hippocampal volume (HV) may be a reliable and measurable surrogate used to assess clinical benefits in early Alzheimer’s disease. The study results, published in the scientific journal CNS Drugs, show that shrinkage of the hippocampus… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Bruno Quinney talks to Dr Mrinal Kammili, Head… Read More
Biotechnology company Mursla Bio has announced a partnership with a pharma company to advance biomarker-guided drug development. While the company has not been named, Mursla Bio says it is a global pharma leader recognised for its expertise in biomarker-guided precision medicine in metabolic dysfunction-associated steatohepatitis (MASH). … Read More
Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More
Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. This webinar, hosted by DDW and supported by Danaher Life Sciences, explores how advanced platforms such as Genedata Profiler… Read More
